Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003636
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer. PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after su... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
08/04/2015
Locations: Hospital de Clinicas "Jose De San Martin", Buenos Aires, Not set +64 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
NCT00421889
Completed
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Gynecologic Oncology Associates, Newport Beach, California +10 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Register for Updates
Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme
NCT01317212
Withdrawn
High-grade gliomas are the commonest primary malignant brain tumours in adults, affecting approximately 5000 people per year in the UK. Standard treatment comprises a combination of surgery, radiotherapy and chemotherapy; however this condition remains incurable and the average survival is approximately 18 months from diagnosis. There are a number of reasons for this. Firstly these tumours are highly invasive and involve important areas of brain making it impossible to remove them surgically or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2015
Locations: Department of Neurosurgery, Bristol, Not set
Conditions: Glioblastoma Multiforme
Register for Updates
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
NCT00254891
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2015
Locations: Pfizer Investigational Site, Little Rock, Alaska +190 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
NCT00735696
Completed
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2014
Locations: ImClone Investigational Site, Beverly Hills, California +8 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
NCT00433498
Completed
RATIONALE: Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pravastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by making tumor cells more sensitive to chemotherapy. It is not yet known whether etoposide and cisplatin or carboplatin are more effective with or without pravastatin in treating small c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2014
Locations: William Harvey Hospital, Ashford-Kent, England +85 locations
Conditions: Lung Cancer
Register for Updates
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
NCT02004093
Completed
This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. The anticipated time on study treatment is 3-12 months.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/25/2014
Locations: Not set, Bruxelles, Not set +33 locations
Conditions: Ovarian Cancer
Register for Updates
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
NCT01166542
Completed
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: University of Alabama at Birmingham, Birmingham, Alabama +76 locations
Conditions: Carcinoma, Squamous Cell of the Head and Neck
Register for Updates
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
NCT00300885
Terminated
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2014
Locations: Not set, Birmingham, Alabama +201 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
NCT00111007
Completed
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2014
Locations: Not set, Birmingham, Alabama +65 locations
Conditions: Melanoma
Register for Updates
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
NCT00700180
Completed
This study will explore the correlation of biomarkers with response rate, and the overall efficacy and safety, of Avastin in combination with carboplatin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer. Patients will be randomized to one of 2 groups, to receive either Avastin 7.5mg/kg iv on day 1 of each 3 week cycle, or Avastin 15mg/kg iv on day 1 of each 3 week cycle; all patients will also receive treatment with carboplatin and either gemcitab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2014
Locations: Not set, St. Leonards, New South Wales +58 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
NCT00122460
Completed
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer. Overall survival will be taken as the primary measure of efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2014
Locations: Research Site, Innsbruck, Not set +69 locations
Conditions: Head and Neck Cancer
Register for Updates